Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Lenvima for Leptomeningeal Metastases
NCT04729348Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in leptomeningeal metastases (LM), sponsored by Massachusetts General Hospital. Started Mar 2021; status: terminated.
02
Drugs
pembrolizumablenvatinib
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT04729348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729348.